Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)
Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemogl...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2024-04, Vol.26 (4), p.1519-1523 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1523 |
|---|---|
| container_issue | 4 |
| container_start_page | 1519 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 26 |
| creator | Moreno‐Pérez, Oscar Reyes‐Garcia, Rebeca Modrego‐Pardo, Inés Doulatram‐Gamgaram, Viyey Kishore Cases, Carlos Casado Guillen‐Morote, Cristina Mendoza, Nieves Arias Tejera‐Pérez, Cristina Cárdenas‐Salas, Jersy Martínez‐Fuster, Sandra Lardiés‐Sánchez, Beatriz Márquez‐Pardo, Rosa Pinés, Pedro Fernández‐García, José Carlos |
| description | Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemoglobin (HbA1c) levels.1-3 Semaglutide is the first and only GLP-1 RA available for oral use. Despite its proven safety and efficacy in randomized clinical trials,4, 5 insights into its real-world use in clinical settings are needed.6We designed the ENDOcrinology Oral Sema Real-World Data (ENDO2S-RWD) study to evaluate the effectiveness, safety and tolerability of oral semaglutide in a large cohort of PLWT2D in Spain. We assessed the factors associated with the clinical response and drug persistence. |
| doi_str_mv | 10.1111/dom.15431 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2907197397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933998687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-66b693d3bbea449c7e75cc998b62ccd37b27389d8d3f9fa5ce7e570ef210da343</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EomXKghdAlti0i7RxnB-bXdUpP1JhpP6IZeTYN8WVEwfbmVF2PALPwWPxJDiTwgKJK0vXi8_n-Ogg9IqkpyTOmbLdKSlySp6gQ5KXNCE0K5_u71nCeJodoBfeP6RpmlNWPUcHlJGC8LI8RD-vQZhf33_srDMKQ9uCDHoLPXiPRa-wFy2ECdsWWycM9tCJezMGrQDrHg9gBwPY6K3u7_FOh684TAPgDCstGgjg3-Jz3Iugbb-b33SjCVpCHxxgB8FZPyyG2DYe3HZPzj5hVBM-vvy83mQ38XvXX9YnR-hZK4yHl497he7eXd5efEiuNu8_XpxfJZIyRpKybEpOFW0aEHnOZQVVISXnrCkzKRWtmqyijCumaMtbUUiooKhSaDOSKkFzukLHi-7g7LcRfKg77SUYI3qwo68znlaEVzSeFXrzD_pgRxcDzBSl0bRkM3WyUDLm9Q7aenC6E26qSVrPBdaxwHpfYGRfPyqOTQfqL_mnsQicLcBOG5j-r1SvN58Wyd-t_6lj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933998687</pqid></control><display><type>article</type><title>Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Moreno‐Pérez, Oscar ; Reyes‐Garcia, Rebeca ; Modrego‐Pardo, Inés ; Doulatram‐Gamgaram, Viyey Kishore ; Cases, Carlos Casado ; Guillen‐Morote, Cristina ; Mendoza, Nieves Arias ; Tejera‐Pérez, Cristina ; Cárdenas‐Salas, Jersy ; Martínez‐Fuster, Sandra ; Lardiés‐Sánchez, Beatriz ; Márquez‐Pardo, Rosa ; Pinés, Pedro ; Fernández‐García, José Carlos</creator><creatorcontrib>Moreno‐Pérez, Oscar ; Reyes‐Garcia, Rebeca ; Modrego‐Pardo, Inés ; Doulatram‐Gamgaram, Viyey Kishore ; Cases, Carlos Casado ; Guillen‐Morote, Cristina ; Mendoza, Nieves Arias ; Tejera‐Pérez, Cristina ; Cárdenas‐Salas, Jersy ; Martínez‐Fuster, Sandra ; Lardiés‐Sánchez, Beatriz ; Márquez‐Pardo, Rosa ; Pinés, Pedro ; Fernández‐García, José Carlos ; SEEN Diabetes Area ; The SEEN Diabetes Area</creatorcontrib><description>Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemoglobin (HbA1c) levels.1-3 Semaglutide is the first and only GLP-1 RA available for oral use. Despite its proven safety and efficacy in randomized clinical trials,4, 5 insights into its real-world use in clinical settings are needed.6We designed the ENDOcrinology Oral Sema Real-World Data (ENDO2S-RWD) study to evaluate the effectiveness, safety and tolerability of oral semaglutide in a large cohort of PLWT2D in Spain. We assessed the factors associated with the clinical response and drug persistence.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.15431</identifier><identifier>PMID: 38151966</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antidiabetics ; Clinical outcomes ; Clinical trials ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; GLP-1 receptor agonists ; Glucagon-Like Peptides - adverse effects ; Humans ; Hypoglycemic Agents - adverse effects ; Patient safety ; Retrospective Studies ; Side effects</subject><ispartof>Diabetes, obesity & metabolism, 2024-04, Vol.26 (4), p.1519-1523</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-66b693d3bbea449c7e75cc998b62ccd37b27389d8d3f9fa5ce7e570ef210da343</citedby><cites>FETCH-LOGICAL-c3881-66b693d3bbea449c7e75cc998b62ccd37b27389d8d3f9fa5ce7e570ef210da343</cites><orcidid>0009-0002-8648-5370 ; 0000-0002-8670-6404 ; 0000-0003-4406-3647 ; 0000-0002-4914-4131 ; 0000-0002-0178-0040 ; 0000-0001-7520-1489 ; 0000-0002-6803-6988 ; 0000-0003-1729-4431 ; 0000-0003-3060-449X ; 0000-0003-2229-8488 ; 0000-0002-2987-5922 ; 0000-0002-2485-484X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.15431$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.15431$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38151966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno‐Pérez, Oscar</creatorcontrib><creatorcontrib>Reyes‐Garcia, Rebeca</creatorcontrib><creatorcontrib>Modrego‐Pardo, Inés</creatorcontrib><creatorcontrib>Doulatram‐Gamgaram, Viyey Kishore</creatorcontrib><creatorcontrib>Cases, Carlos Casado</creatorcontrib><creatorcontrib>Guillen‐Morote, Cristina</creatorcontrib><creatorcontrib>Mendoza, Nieves Arias</creatorcontrib><creatorcontrib>Tejera‐Pérez, Cristina</creatorcontrib><creatorcontrib>Cárdenas‐Salas, Jersy</creatorcontrib><creatorcontrib>Martínez‐Fuster, Sandra</creatorcontrib><creatorcontrib>Lardiés‐Sánchez, Beatriz</creatorcontrib><creatorcontrib>Márquez‐Pardo, Rosa</creatorcontrib><creatorcontrib>Pinés, Pedro</creatorcontrib><creatorcontrib>Fernández‐García, José Carlos</creatorcontrib><creatorcontrib>SEEN Diabetes Area</creatorcontrib><creatorcontrib>The SEEN Diabetes Area</creatorcontrib><title>Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemoglobin (HbA1c) levels.1-3 Semaglutide is the first and only GLP-1 RA available for oral use. Despite its proven safety and efficacy in randomized clinical trials,4, 5 insights into its real-world use in clinical settings are needed.6We designed the ENDOcrinology Oral Sema Real-World Data (ENDO2S-RWD) study to evaluate the effectiveness, safety and tolerability of oral semaglutide in a large cohort of PLWT2D in Spain. We assessed the factors associated with the clinical response and drug persistence.</description><subject>Antidiabetics</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon-Like Peptides - adverse effects</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Patient safety</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS0EomXKghdAlti0i7RxnB-bXdUpP1JhpP6IZeTYN8WVEwfbmVF2PALPwWPxJDiTwgKJK0vXi8_n-Ogg9IqkpyTOmbLdKSlySp6gQ5KXNCE0K5_u71nCeJodoBfeP6RpmlNWPUcHlJGC8LI8RD-vQZhf33_srDMKQ9uCDHoLPXiPRa-wFy2ECdsWWycM9tCJezMGrQDrHg9gBwPY6K3u7_FOh684TAPgDCstGgjg3-Jz3Iugbb-b33SjCVpCHxxgB8FZPyyG2DYe3HZPzj5hVBM-vvy83mQ38XvXX9YnR-hZK4yHl497he7eXd5efEiuNu8_XpxfJZIyRpKybEpOFW0aEHnOZQVVISXnrCkzKRWtmqyijCumaMtbUUiooKhSaDOSKkFzukLHi-7g7LcRfKg77SUYI3qwo68znlaEVzSeFXrzD_pgRxcDzBSl0bRkM3WyUDLm9Q7aenC6E26qSVrPBdaxwHpfYGRfPyqOTQfqL_mnsQicLcBOG5j-r1SvN58Wyd-t_6lj</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Moreno‐Pérez, Oscar</creator><creator>Reyes‐Garcia, Rebeca</creator><creator>Modrego‐Pardo, Inés</creator><creator>Doulatram‐Gamgaram, Viyey Kishore</creator><creator>Cases, Carlos Casado</creator><creator>Guillen‐Morote, Cristina</creator><creator>Mendoza, Nieves Arias</creator><creator>Tejera‐Pérez, Cristina</creator><creator>Cárdenas‐Salas, Jersy</creator><creator>Martínez‐Fuster, Sandra</creator><creator>Lardiés‐Sánchez, Beatriz</creator><creator>Márquez‐Pardo, Rosa</creator><creator>Pinés, Pedro</creator><creator>Fernández‐García, José Carlos</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0002-8648-5370</orcidid><orcidid>https://orcid.org/0000-0002-8670-6404</orcidid><orcidid>https://orcid.org/0000-0003-4406-3647</orcidid><orcidid>https://orcid.org/0000-0002-4914-4131</orcidid><orcidid>https://orcid.org/0000-0002-0178-0040</orcidid><orcidid>https://orcid.org/0000-0001-7520-1489</orcidid><orcidid>https://orcid.org/0000-0002-6803-6988</orcidid><orcidid>https://orcid.org/0000-0003-1729-4431</orcidid><orcidid>https://orcid.org/0000-0003-3060-449X</orcidid><orcidid>https://orcid.org/0000-0003-2229-8488</orcidid><orcidid>https://orcid.org/0000-0002-2987-5922</orcidid><orcidid>https://orcid.org/0000-0002-2485-484X</orcidid></search><sort><creationdate>202404</creationdate><title>Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)</title><author>Moreno‐Pérez, Oscar ; Reyes‐Garcia, Rebeca ; Modrego‐Pardo, Inés ; Doulatram‐Gamgaram, Viyey Kishore ; Cases, Carlos Casado ; Guillen‐Morote, Cristina ; Mendoza, Nieves Arias ; Tejera‐Pérez, Cristina ; Cárdenas‐Salas, Jersy ; Martínez‐Fuster, Sandra ; Lardiés‐Sánchez, Beatriz ; Márquez‐Pardo, Rosa ; Pinés, Pedro ; Fernández‐García, José Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-66b693d3bbea449c7e75cc998b62ccd37b27389d8d3f9fa5ce7e570ef210da343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidiabetics</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon-Like Peptides - adverse effects</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Patient safety</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno‐Pérez, Oscar</creatorcontrib><creatorcontrib>Reyes‐Garcia, Rebeca</creatorcontrib><creatorcontrib>Modrego‐Pardo, Inés</creatorcontrib><creatorcontrib>Doulatram‐Gamgaram, Viyey Kishore</creatorcontrib><creatorcontrib>Cases, Carlos Casado</creatorcontrib><creatorcontrib>Guillen‐Morote, Cristina</creatorcontrib><creatorcontrib>Mendoza, Nieves Arias</creatorcontrib><creatorcontrib>Tejera‐Pérez, Cristina</creatorcontrib><creatorcontrib>Cárdenas‐Salas, Jersy</creatorcontrib><creatorcontrib>Martínez‐Fuster, Sandra</creatorcontrib><creatorcontrib>Lardiés‐Sánchez, Beatriz</creatorcontrib><creatorcontrib>Márquez‐Pardo, Rosa</creatorcontrib><creatorcontrib>Pinés, Pedro</creatorcontrib><creatorcontrib>Fernández‐García, José Carlos</creatorcontrib><creatorcontrib>SEEN Diabetes Area</creatorcontrib><creatorcontrib>The SEEN Diabetes Area</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno‐Pérez, Oscar</au><au>Reyes‐Garcia, Rebeca</au><au>Modrego‐Pardo, Inés</au><au>Doulatram‐Gamgaram, Viyey Kishore</au><au>Cases, Carlos Casado</au><au>Guillen‐Morote, Cristina</au><au>Mendoza, Nieves Arias</au><au>Tejera‐Pérez, Cristina</au><au>Cárdenas‐Salas, Jersy</au><au>Martínez‐Fuster, Sandra</au><au>Lardiés‐Sánchez, Beatriz</au><au>Márquez‐Pardo, Rosa</au><au>Pinés, Pedro</au><au>Fernández‐García, José Carlos</au><aucorp>SEEN Diabetes Area</aucorp><aucorp>The SEEN Diabetes Area</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD)</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2024-04</date><risdate>2024</risdate><volume>26</volume><issue>4</issue><spage>1519</spage><epage>1523</epage><pages>1519-1523</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><abstract>Type 2 diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and/or sodium-glucose co-transporter-2 inhibitors for people living with type 2 diabetes (PLWT2D) with an established or high risk of cardiovascular disease and/or renal disease, regardless of glycated haemoglobin (HbA1c) levels.1-3 Semaglutide is the first and only GLP-1 RA available for oral use. Despite its proven safety and efficacy in randomized clinical trials,4, 5 insights into its real-world use in clinical settings are needed.6We designed the ENDOcrinology Oral Sema Real-World Data (ENDO2S-RWD) study to evaluate the effectiveness, safety and tolerability of oral semaglutide in a large cohort of PLWT2D in Spain. We assessed the factors associated with the clinical response and drug persistence.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>38151966</pmid><doi>10.1111/dom.15431</doi><tpages>5</tpages><orcidid>https://orcid.org/0009-0002-8648-5370</orcidid><orcidid>https://orcid.org/0000-0002-8670-6404</orcidid><orcidid>https://orcid.org/0000-0003-4406-3647</orcidid><orcidid>https://orcid.org/0000-0002-4914-4131</orcidid><orcidid>https://orcid.org/0000-0002-0178-0040</orcidid><orcidid>https://orcid.org/0000-0001-7520-1489</orcidid><orcidid>https://orcid.org/0000-0002-6803-6988</orcidid><orcidid>https://orcid.org/0000-0003-1729-4431</orcidid><orcidid>https://orcid.org/0000-0003-3060-449X</orcidid><orcidid>https://orcid.org/0000-0003-2229-8488</orcidid><orcidid>https://orcid.org/0000-0002-2987-5922</orcidid><orcidid>https://orcid.org/0000-0002-2485-484X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2024-04, Vol.26 (4), p.1519-1523 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2907197397 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antidiabetics Clinical outcomes Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy GLP-1 receptor agonists Glucagon-Like Peptides - adverse effects Humans Hypoglycemic Agents - adverse effects Patient safety Retrospective Studies Side effects |
| title | Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S‐RWD) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A29%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90world%20effectiveness%20and%20safety%20of%20oral%20semaglutide%20in%20people%20living%20with%20type%202%20diabetes:%20A%20nationwide%20multicentre%20retrospective%20observational%20study%20(ENDO2S%E2%80%90RWD)&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Moreno%E2%80%90P%C3%A9rez,%20Oscar&rft.aucorp=SEEN%20Diabetes%20Area&rft.date=2024-04&rft.volume=26&rft.issue=4&rft.spage=1519&rft.epage=1523&rft.pages=1519-1523&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.15431&rft_dat=%3Cproquest_cross%3E2933998687%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2933998687&rft_id=info:pmid/38151966&rfr_iscdi=true |